The benefits of investments to combat HIV, tuberculosis and malaria for primary health care, 2000-23: an economic modeling analysis

Authors: Jiaying Stephanie Su [1,2], John Stover [3], Carel Pretorius [3], Peter Winskill [4,5], Timothy B. Hallett [4,5], Nicolas A. Menzies [1,2]

Affiliations:

1. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
2. Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
3. Avenir Health, Glastonbury, Connecticut, USA.
4. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
5. MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.

Corresponding Author: Jiaying Stephanie Su (stephaniesu@hsph.harvard.edu), Nicolas A. Menzies (nmenzies@hsph.harvard.edu)

Word Count: 3242

Abstract

Background: Investments to combat HIV, tuberculosis, and malaria (HTM) have delivered substantial health gains in high-burden settings. There is limited evidence on how this has affected primary health care (PHC). We estimated the changes in PHC utilization and associated cost savings resulting from scale-up of HTM interventions in 108 low- and middle-income countries over 2000–2023.

Methods: For each disease, we applied validated mathematical models quantifying the incremental differences in PHC outpatient visits and inpatient bed-days by individuals with untreated symptomatic HIV, tuberculosis, or malaria. By country and year, we compared the actual scale-up of HTM services scenario against a counterfactual scenario holding HTM intervention coverage constant at year 2000 levels. We estimated the cost savings associated with these utilization reductions, and compared results to national hospital capacity and health expenditure.

Findings: Over 2000–2023, scale-up of HTM services averted an estimated 6·9 (95% interval: 4·4–10·4) billion PHC outpatient visits and 3·9 (2·5–6·1) billion inpatient bed-days, equivalent to US$135 (77–225) billions in total cost savings. Reductions in utilization and cost savings were greatest in the Sub-Saharan Africa and East Asia and Pacific regions. For 2023, a median of 4·4% of hospital bed capacity and 1·6% of government health expenditures were freed-up across study countries. These percentages were 22·9% and 5·1% respectively for low-income countries.

Interpretation: Sustained investments in HTM services in high-burden settings generated substantial cost savings over recent decades through reduced PHC utilization. These benefits should be considered when assessing investment impact.

Funding: The Global Fund.

Introduction

Since 2000, global efforts to combat HIV, tuberculosis (TB), and malaria have reduced the incidence of HIV by 54%, TB by 26%, and malaria by 24%.[1-3] These achievements would not have been possible without sustained investments to scale-up interventions that prevent and treat these diseases. These investments have been made by both domestic governments and international partners, with funding provided through bilateral mechanisms such as the U.S. government's President's Emergency Plan for AIDS Relief (PEPFAR) and multilateral mechanisms such as the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). In 2023, approximately US$30 billion was spent by both domestic and international partners to advance HIV, TB, and malaria (HTM) elimination in low- and middle-income countries (LMICs),[1-3] reflecting global commitment to ending these epidemics.

Analyses of investments to address HIV, TB, and malaria (HTM) have typically compared the health benefits generated by these interventions to the resources required to scale and maintain HTM-specific services.[4-6] However, less attention has been directed toward the implications for primary health care (PHC), except when these services are involved in providing HTM interventions. Although normative guidelines for economic evaluation stress the value of considering broader societal consequences,[7] evidence on the impact of HTM investments on health systems remains inconclusive. Concerns have been raised that global health initiatives may distort incentives within the health system and undermine health services for non-targeted conditions, while reviews of empirical studies have documented both positive and negative effects.[8,9] These studies highlight the need to quantify the implications of disease-specific investments on health systems, especially given that they do not explicitly examine counterfactual scenarios involving different levels of investment. From the demand side, the indirect benefits of HTM investments on PHC can arise through multiple mechanisms. First, effective disease-specific care funded through HTM programs can reduce the number of individuals experiencing

untreated symptomatic disease, crowding out care that would otherwise be sought from PHC providers.

Second, improved HTM care can prevent progression to advanced illness, mitigating the need for

inpatient care. Third, better HTM prevention and treatment can interrupt disease transmission, curbing

epidemic spread and leading to fewer symptomatic individuals requiring care. Each of these represents

mechanism through which HTM investments can potentially reduce the demand for PHC, a benefit that

could be particularly valuable in highly disease-affected countries where health care resources are

scarce.

In the context of evolving global priorities and growing fiscal constraints, it is important to understand

not only the direct outcomes of disease-specific investments but also their broader implications for

health system capacity and expenditure. In this study, we estimated the impact of investments to scale-

up HIV, TB, and malaria services on primary health care utilization and the associated cost savings in 108

low- and middle-income countries, from 2000 to 2023.

Methods

Population and analytic scenarios

We considered individuals with or at risk of HIV, TB, or malaria in LMICs with a significant burden of one

of these conditions, and for which epidemiological outcomes were available from validated disease

simulation models for each disease.[10-12] We included 108 countries for HIV, 51 countries for TB, and 55

countries for malaria in our analysis, representing 94% global HIV prevalence, 92% of global TB incidence

and 90% of global malaria incidence in 2023.

For each disease, we compared two scenarios covering years 2000-2023: an *actual scenario* reflecting

the observed scale-up of HTM interventions in each country since year 2000, and a counterfactual

constant coverage scenario holding HTM intervention coverage fixed at year 2000 levels for each

country. In sensitivity analyses, we compared the *actual scenario* to a counterfactual *no coverage*

scenario in which HTM intervention coverage was tuned down to zero from year 2000 onward for each

country throughout the study period. Scenarios were assumed to be identical prior to year 2000.

Estimation of disease epidemiology

We obtained epidemiological outcomes for each disease and scenario by country and year from models

employed for the Global Fund 8th replenishment investment case.[13] These models included the *Goals*

Model for HIV, the *Global Portfolio TB Model* for TB, and the *malariasimulation* model for malaria.[10-12]

For the *actual scenario*, models were calibrated to reproduce the historic scale-up HTM intervention

coverage in each country over the study period, as recorded in the official estimates published by WHO

and UNAIDS.[2,3,14] For the *constant coverage scenario*, HTM intervention coverage—defined as the

fraction of eligible individuals receiving each service—was held constant at year 2000 levels for the full

study period with all other modeled mechanisms (e.g., demographic processes, intervention quality)

followed the same assumptions as the *actual scenario*. For TB, we used the modeled results from the

Global Portfolio TB Model (29 countries) to train a regression-based emulator, which was implemented

to simulate epidemiological outcomes for an additional 22 countries identified in the WHO lists of high

TB burden countries.[2] This increased the fraction of global TB incidence represented by countries in the

analysis from 81% to 92%.

Estimation of averted PHC utilization

We used the modeled epidemiological estimates to calculate the differences in the number of

individuals with untreated symptomatic HIV, TB, and malaria by country and year between the *actual*

scenario and the counterfactual scenarios. These differences represent the changes in epidemiological

outcomes achieved by scale-up of HTM services over the study period. To translate these into measures of averted PHC utilization, we applied estimates of the additional outpatient care (number of outpatient clinic visits) and inpatient care (number of hospital bed-days) received by affected individuals, as compared to individuals without these conditions. We assumed no additional PHC utilization once individuals were initiated on HTM-specific treatment. Approaches for each disease are summarized below, with model structures and input parameters detailed in the supplement (Figure S-1, Table S-1).

HIV: By country and year, we computed the difference in the number of person-years spent by individuals with untreated HIV between scenarios, stratified into health states defined by age group and CD4 cell count category. To estimate averted PHC outpatient visits, we multiplied this difference by the additional outpatient visits per person-year for each health state as compared to HIV-negative individuals. To estimate averted inpatient utilization, we multiplied the difference in the number of untreated HIV person-years with untreated HIV by the rate of excess hospitalization for these individuals and the average duration of hospital stay.

TB: By country and year, we calculated the differences in TB incidence between scenarios, stratified by whether or not these individuals received TB treatment. For those receiving TB treatment, we allowed for additional PHC utilization during the pre-treatment period, multiplying the difference in the number of treated cases by the additional outpatient visits per TB case. For untreated individuals, we applied the additional outpatient visits per TB case over the whole disease episode (i.e., until death or self-cure) to the difference in the number of untreated cases. We summed values for treated and untreated TB to derive the total averted outpatient utilization. The averted inpatient utilization was computed by multiplying the difference of individuals with untreated TB between scenarios by the proportion

hospitalized (conservatively assumed to be restricted to those dying with untreated TB) and the average duration of hospitalization.

Malaria: By country and year, we estimated the number of averted outpatient visits by multiplying the difference in the number of individuals with untreated symptomatic malaria between scenarios by published rates of care-seeking, adjusted for differences in access to care. For averted inpatient utilization, we applied the probabilities of hospitalization for uncomplicated and severe malaria to the differences in the number of individuals with respective malaria disease. We summed these results, subtracted out those who were hospitalized with malaria and received treatment, then multiplied the remainder by the average duration of hospital stay to obtain the estimates of averted inpatient bed-days.

Estimation of cost savings

We estimated cost savings associated with averted PHC utilization by applying country-specific unit costs to the estimates of averted outpatient visits and inpatient bed-days. Unit costs were retrieved from WHO-CHOICE estimates and adjusted for inflation to reflect nominal U.S. dollars by year.[15-17]

Outcomes

The primary outcomes are the averted PHC outpatient visits, inpatient bed-days, and the associated cost savings resulting from the observed scale-up of HIV, TB, and malaria services across modeled countries over the study period. Results are reported by disease, country, year, World Bank region, and income classification. To contextualize the findings, we also expressed averted inpatient utilization as a percentage of national hospital bed-days capacity, and cost savings as a percentage of domestic government health expenditures.[18,19]

We used second-order Monte Carlo simulation (probabilistic sensitivity analysis) to quantify uncertainty in analytic outcomes.[20] We specified probability distributions for each uncertain parameter (Table S-1), and drew 1000 parameter samples using a Latin hypercube design. We used these samples to generate 1000 estimates for each study outcome and calculated equal-tailed 95% uncertainty intervals from the distribution of results. We calculated partial-rank correlation coefficients (PRCCs) to assess the relative importance of individual parameters in determining total cost savings for each disease.[21] All analyses were conducted in R (version 4.4.1).

Results

Freed-up primary health care resources

From 2000 to 2023 inclusive, we estimated substantial reductions in PHC utilization due to scale-up of HIV, TB, and malaria services in the selected 108 countries, with a total incremental reduction of 6·9 (95% uncertainty interval: 4·4–10·4) billion outpatient visits and 3·9 (2·5–6·1) billion inpatient bed-days (Table 1). This reduced utilization was equivalent to US$135 (77–225) billion in cost savings. The largest reductions in PHC utilization were estimated for the Sub-Saharan Africa (SSA) and East Asia and Pacific (EAP) regions. In the SSA region, where reductions in utilization were greatest for HIV and malaria, the scale-up of HIV services was estimated to have averted 0·9 (0·6–1·3) billion outpatient visits and 1·1 (0·4–2·2) billion inpatient bed-days over the study period, translating into US$43 (14–101) billion in cost savings (Table S-2). For malaria, the scale-up of services in SSA was estimated to have averted 2·3 (1·3–3·6) billion outpatient visits and 0·3 (0·2–0·6) billion inpatient bed-days, corresponding to US$4·9 (3·0–7·4) billion in cost savings. Scale-up of TB services contributed a notable portion of utilization reductions

in the EAP region, averting 1·7 (0·6–3·6) billion outpatient visits and 1·0 (0·5–1·8) billion inpatient bed

days, representing US$53 (26–99) billion in cost savings between 2000 and 2023.

[Table 1]

The amount of averted utilization and cost savings both grew annually over the study period, with 2020–

2023 alone accounting for 34% of total averted utilization and 38% of total cost savings. Figure 1

presents the trend of these outcomes (per 100 population) over the study period for the highest-burden

countries for each disease. In 2023, per 100 population, nearly 100 HIV-related outpatient visits were

averted in Eswatini, and close to 80 bed-days were averted in Botswana and South Africa. Total cost

savings per 100 population reached over US$7500 in Botswana. Similar trends were observed for TB and

malaria, for which substantial reductions in PHC utilization and associated cost savings were achieved in

high disease-burden countries. Although the incremental benefits continued to rise, we saw a

deceleration in growth of these gains for most countries towards the end of the study period.

[Figure 1]

Impact on health care capacity

We compared the estimated averted inpatient bed-days to published estimates of hospital bed capacity

for each country, to assess the magnitude of reduced utilization relative to existing health system

capacity (Figure 2). For a minority of countries, the combined cumulative reductions in bed-days across

all three diseases represented a substantial share of total hospital bed capacity over the study period.

This was particularly true in the SSA region, where estimated reductions in hospital utilization were over

50% of national hospital bed capacity for eight countries, including Botswana (70%), Lesotho (67%), and

Ethiopia (67%). Across all SSA countries, the median reduction was 18·0% (interquartile range (IQR): 7·8–34·4) over the entire study period and 31·8% (IQR: 9·2–54·7) for 2023 (Table 2). An estimated 22·9% (IQR: 8·7–53·1) of hospital bed-days were averted in low-income countries for the final year, which was almost 4 times greater than the 6·3% (IQR: 1·2–22·3) in lower-middle-income countries and 13 times the percentages (1·7%, IQR: 0·5–3·5) in upper-middle-income countries.

[Figure 2]

[Table 2]

Impact on health care spending

To put the scale of financial benefits into perspective, we expressed the cost savings as a fraction of external estimates of domestic government health expenditures. In 2023, the estimated cost savings represented a median of 1·6% (IQR: 0·2–5·9%) of total government health spending across the 108 modeled countries (Table 2). These percentages were higher for low-income countries (median in 2023: 5·1%, IQR: 2·7–14·0) compared to lower-middle-income countries (median in 2023: 2·0%, IQR: 0·4–6·6) and upper-middle-income countries (median in 2023: 0·3%, IQR: 0·08–1·2). In proportion to country-level health care spending, the highest percentages of cost savings were seen among countries with lower levels of economic development. Values for countries in the SSA region clustered around the 10% reference line, with cost savings for 2023 surpassing 20% of government health spending in 12 out of 47 countries in this region (Figure 3).

[Figure 3]

Tables S-3 and S-4 report incremental reductions in PHC utilization, the associated cost savings, and their relative health care capacity and spending impact, comparing the *actual scenario* to the *no coverage scenario*, which assumed no HTM interventions after the year 2000. These results were larger in magnitude than those from the main analysis. An estimated 18·3 (10·3–29·7) billion outpatient visits and 10·1 (6·2–15·5) billion inpatient bed-days were averted – 2·6 times greater than the values reported in the main analysis. Cost savings from comparing these scenarios totaled US$358 (211–583) billion over the study period, 2·7 times higher than estimated in the main analysis estimate. Figure S-2 presents PRCCs describing the relationship between individual parameters and estimated total cost savings for each disease. For HIV and TB, the most influential factors associated with the estimated cost savings were the length of hospital stays and the unit cost per hospital bed-day. For malaria, the strongest determinants were the difference in malaria cases between scenarios, the number of outpatient visits per malaria case, and the unit cost per outpatient visit.

Discussion

In this study we investigated how investments to scale-up of HIV, TB, and malaria services have influenced primary health care in 108 low- and middle-income countries. We estimated substantial reductions in PHC utilization during 2000–2023, with 6·9 billion outpatient visits and 3·9 billion inpatient bed-days averted over the period, as compared to a counterfactual scenario constraining intervention coverage at year 2000 levels. These reductions in utilization generated total cost savings equivalent to US$135 billion. These impacts suggest an additional benefit of investments in HTM interventions that are not usually captured in other analyses. Additionally, for several countries—particularly those with high disease burden and limited health system capacity—the reductions in hospital utilization and cost savings were large relative to national hospital capacity and government health care spending.

Several previous studies have suggested pathways through which investments to combat HIV, TB, and malaria can enhance health service delivery, improve medical supply chain, and facilitate human resources for health in low- and middle-income countries.[22-24] Results of this study demonstrate another mechanism through which these investments can complement health system strengthening. This work adds to the body of literature documenting the wider consequences of global health initiatives to address specific diseases in resource-limited settings, which have reported both positive and negative effects.[25-28] Under the *constant coverage* counterfactual scenario to which we compared the *actual scenario*, low HTM service coverage allowed continued evolution and growth of these epidemics. Any reductions in disease burden achieved pre-2000 plateaued and reversed, or in the case of HIV, expanded. As a consequence, low HTM service coverage was projected to produce an increasing number of individuals with untreated, symptomatic disease who would seek primary care when they became ill, and potentially require hospitalization with the development of advance disease. In the sensitivity analysis where we examined the *no coverage* counterfactual scenario, each of the three epidemics were projected to expanded unchecked, leading to large numbers of symptomatic individuals seeking primary health care in subsequent years. These analyses clarify the appropriate comparator when assessing efforts to combat HTM epidemics. Rather than a comparison between whether or not services are provided for these three diseases, the results of this study show the appropriate comparison to be whether *effective* or *ineffective* services are provided for these diseases, as individuals with symptomatic disease will seek and receive some form of medical care regardless of whether that care is deliberately planned and effective, even in settings with limited health system capacity.

Overall, our estimates showed progressive growth in the magnitude of averted PHC utilization and cost savings over the study period as HTM services were scaled up and the compounding benefits of

transmission reductions were realized. An exception to this pattern was malaria, for which we identified fluctuations in the time trends of estimated outcomes for some countries and years especially around 2020. These were likely attributable to resurgences of malaria incidence driven by a change of funding mechanisms, pandemic-related disruptions, and differences in the timing of campaign interventions between scenarios.[29-31] This finding reveals how interruptions in intervention access can have secondary consequences on other health care, adding resource and financial burdens to the already strained primary health care systems.

This study has several limitations. First, we did not consider reductions in healthcare utilization resulting from pre-mature mortality. It is possible that the incremental reductions in PHC utilization we estimated would be partially offset by the future utilization of individuals whose deaths were averted as a consequence of scaled-up of HTM services. Second, there were limited published estimates for several analytic inputs describing the health care utilization of individuals with untreated HIV, TB, or malaria, which introduced uncertainties into our estimates. Third, our analysis did not consider changes in supply-side health system dynamics or constraints. These would influence how freed-up capacity in PHC systems is absorbed and utilized. Fourth, although we calculated our outcomes using country-level epidemiological data, several analytic inputs were only available as global averages or were translated to different country settings using regression adjustments. For this reason, outcomes for individual countries should be interpreted with caution, and the ideal country-specific analysis would require a more granular representation of country-specific health system structures, financing mechanisms, and service delivery models. Given these limitations, further research is needed to illuminate the societal and economic impact of investments to combat major infectious diseases across different LMIC settings, including how supply-side factors play a role in mediating these outcomes. Better evidence on care

seeking and health outcomes for populations with untreated symptomatic diseases in the context of care access barriers would also be valuable for describing the full effects of these investments.

Our analysis offers novel evidence on how investments to scale-up HIV, TB, and malaria services over the start of the 21st century have freed-up primary health care resources, and produced major cost savings. Our results highlight the importance of recognizing not only the direct health and economic gains from these investments, but also the indirect benefits for primary health systems. Our findings carry possible policy implications for global health financing and priority setting, and underscore the positive contribution that sustained support by international donors and domestic governments for HIV, TB, and malaria elimination can make to the broader agenda of promoting health system resilience and efficiency.

Funding

NM, TBH, CP, JS, and PW acknowledge support from the Global Fund to Fight AIDS, TB, and Malaria. PW acknowledges support from the Bill & Melinda Gates Foundation (INV-043624). TBH and PW acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.

Acknowledgements

The authors thank Mehran Hosseini, Richard Grahn, Mikaela Smit, and Johannes Hunger, as well as members of the Global Fund Modeling Guidance Group, for feedback on early versions of this analysis.

Author Contributions

NAM conceptualized the study. NAM and JSS designed the analysis in collaboration with all authors. JS, CP, and PW conducted epidemiological modeling. JSS conducted the analysis, produced the results, and drafted the manuscript. NAM and JSS revised the manuscript. All authors reviewed and contributed to the final version of the manuscript.

References

1.   UNAIDS. Global HIV & AIDS statistics - Fact sheet 2024, 2024.

2.   World Health Organization. Global tuberculosis report 2024. Geneva, Switzerland, 2024.

3.   World Health Organization. World Malaria Report 2024. Geneva, Switzerland, 2024.

4.   Eaton JW, Menzies NA, Stover J, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. *Lancet Glob Health* 2014; **2**(1): e23-34.

5.   Menzies NA, Gomez GB, Bozzani F, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. *Lancet Glob Health* 2016; **4**(11): e816-e26.

6.   Penny MA, Verity R, Bever CA, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. *Lancet* 2016; **387**(10016): 367-75.

7.   Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE. *Int J Health Policy Manag* 2021; **10**(11): 673-7.

8.   Samb B, Evans T, Dybul M, et al. An assessment of interactions between global health initiatives and country health systems. *Lancet* 2009; **373**(9681): 2137-69.

9.   El-Sadr WM, Abrams EJ. Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings? *AIDS* 2007; **21 Suppl 5**: S65-70.

10.   Stover J, Glaubius R, Teng Y, et al. Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. *PLoS Med* 2021; **18**(10): e1003831.

11.   Pretorius C. GlobalPortfolioModel. 2025. https://github.com/CarelPretorius/GlobalTBPortfolioModel (accessed Mar 21 2025).

12.   Griffin JT, Bhatt S, Sinka ME, et al. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. *Lancet Infect Dis* 2016; **16**(4): 465-72.

13.   The Global Fund. Investment Case Eighth Replenishment 2025, 2025.

14.   UNAIDS. The ugency of now. AIDS at a crossroads 2024 global AIDS update, 2024.

15.   International Monetary Fund. World Economic Outlook Database, April 2024, GDP Deflator. 2024. https://www.imf.org/en/Publications/WEO/weo-database/2024/April (accessed Oct 16 2024).

16.   Stenberg K, Lauer JA, Gkountouras G, Fitzpatrick C, Stanciole A. Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery. *Cost Effectiveness and Resource Allocation* 2018; **16**(1): 11.

17.   International Monetary Fund. International Financial Statistics (IFS), Exchange Rates. 2024.

18.   World Health Organization. The Global Health Observatory: Hospital beds (per 10 000 population). 2024. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hospital-beds-(per-10-000-population) (accessed Dec 17 2024).

19.   World Health Organization. Global Health Expenditure Database. 2024. https://apps.who.int/nha/database/select/indicators/en (accessed Dec 17 2024).

20.   Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. *Med Decis Making* 2012; **32**(5): 722-32.

21.   Iman RL, Helton JC. An investigation of uncertainty and sensitivity analysis techniques for computer models. *Risk analysis* 1988; **8**(1): 71-90.

22. Hemingway CD, Bella Jalloh M, Silumbe R, et al. Pursuing health systems strengthening through disease-specific programme grants: experiences in Tanzania and Sierra Leone. *BMJ Glob Health* 2021; **6**(10).

23. Mangal TD, Molaro M, Nkhoma D, et al. A Decade of Progress in HIV, Malaria, and Tuberculosis Initiatives in Malawi. *medRxiv* 2024.

24. Phillips DE, Ambrosio G, Batzel A, et al. Bringing a health systems modelling approach to complex evaluations: multicountry applications in HIV, TB and malaria. *BMJ Glob Health* 2020; **5**(11).

25. Crown W, Hariharan D, Kates J, et al. Analysis of economic and educational spillover effects in PEPFAR countries. *PLoS One* 2023; **18**(12): e0289909.

26. Rasschaert F, Pirard M, Philips MP, et al. Positive spill-over effects of ART scale up on wider health systems development: evidence from Ethiopia and Malawi. *J Int AIDS Soc* 2011; **14 Suppl 1**(Suppl 1): S3.

27. Chima CC, Franzini L. Spillover effect of HIV-specific foreign aid on immunization services in Nigeria. *Int Health* 2016; **8**(2): 108-15.

28. Ibeneme S, Croke K, Karamagi H, Bump J, Okeibunor J. Spillover Effects of HIV Foreign Aid on the Delivery of Maternal and Child Health Services in Nigeria: 2008 – 2018. *Research Square* 2021.

29. Dzianach PA, Rumisha SF, Lubinda J, et al. Evaluating COVID-19-Related Disruptions to Effective Malaria Case Management in 2020-2021 and Its Potential Effects on Malaria Burden in Sub-Saharan Africa. *Trop Med Infect Dis* 2023; **8**(4).

30. Zelman B, Melgar M, Larson E, Phillips A, Shretta R. Global fund financing to the 34 malaria-eliminating countries under the new funding model 2014-2017: an analysis of national allocations and regional grants. *Malar J* 2016; **15**: 118.

31. Park J, Kang S, Seok D, et al. Barriers against and strategies for malaria control during the COVID-19 pandemic in low- and middle-income countries: a systematic review. *Malar J* 2023; **22**(1): 41.

32.   World Health Organization. The Global Health Observatory: HIV – Prevalence of HIV among

adults aged 15 to 49 (%). 2023. https://www.who.int/data/gho/data/indicators/indicator-

details/GHO/prevalence-of-hiv-among-adults-aged-15-to-49-(-) (accessed Mar 13 2025).

33.   World Health Organization. The Global Health Observatory: Estimated malaria incidence (per

1000 population at risk). 2024. https://www.who.int/data/gho/data/indicators/indicator-

details/GHO/malaria-incidence-(per-1-000-population-at-risk) (accessed Mar 19 2025).

34.   World Health Organization. WHO TB burden estimates. 2024.

https://www.who.int/teams/global-tuberculosis-programme/data (accessed Nov 8 2024).

Tables

	Averted utilization, millions		Cost savings (US$), millions		
	Outpatient visits	Inpatient bed-days	Outpatient	Inpatient	Total
Total	6926 (4362, 10447)	3896 (2465, 6097)	20613 (11059, 37265)	114093 (60711, 202463)	134706 (77101, 225215)
Disease					
HIV	1188 (757, 1734)	1352 (516, 2710)	4054 (2311, 6263)	49958 (16521, 112597)	54012 (20390, 117874)
TB	3303 (1127, 6816)	2150 (1164, 3579)	13496 (4388, 29199)	61327 (28490, 114771)	74822 (39769, 131455)
Malaria	2435 (1371, 3872)	395 (184, 767)	3063 (1636, 4951)	2808 (1223, 5831)	5871 (3550, 9196)
World Bank region					
East Asia and Pacific	1837 (705, 3751)	1129 (621, 1856)	10438 (3479, 23240)	48901 (22440, 93909)	59338 (29848, 109141)
Europe and Central Asia	207 (87, 398)	95 (57, 149)	912 (375, 1831)	3419 (1909, 5737)	4331 (2570, 6820)
Latin America and Caribbean	245 (134, 421)	156 (89, 256)	819 (477, 1350)	4359 (2078, 7877)	5178 (2829, 8762)
Middle East and North Africa	5.2 (3.5, 7.4)	3.8 (1.6, 7.3)	28 (16, 43)	169 (65, 359)	197 (90, 390)
South Asia	791 (364, 1419)	594 (356, 936)	1255 (513, 2457)	5874 (2759, 11025)	7130 (3827, 12366)
Sub-Saharan Africa	3841 (2592, 5355)	1918 (1151, 3146)	7162 (4697, 10385)	51370 (22185, 111957)	58531 (28442, 118874)
Income classification					
Low income	1914 (1231, 2771)	624 (413, 925)	1649 (1020, 2465)	2437 (1479, 4167)	4086 (2890, 5908)
Lower middle income	2700 (1725, 4033)	1431 (927, 2146)	4777 (2920, 7256)	15022 (9060, 24073)	19799 (13323, 28931)
Upper middle income	2312 (1065, 4437)	1841 (1038, 3046)	14187 (6162, 28254)	96634 (47386, 180137)	110821 (58237, 197967)
Time period					
2000-2009	865 (542, 1308)	504 (318, 772)	1596 (907, 2701)	10182 (5725, 17093)	11778 (7094, 19028)
2010-2019	3710 (2356, 5554)	2068 (1316, 3234)	10789 (5913, 19159)	61575 (32350, 109722)	72364 (41265, 122863)
2020-2023	2351 (1436, 3594)	1324 (824, 2084)	8228 (4220, 15273)	42335 (22107, 75114)	50564 (29181, 84447)

Table 1. Cumulative incremental reductions in primary health care utilization and cost savings due to scale-up HIV, TB, and malaria services, for actual scenario compared to constant coverage scenario, 2000-23.

Values in parentheses represent 95% uncertainty intervals. Cost values represent nominal U.S. dollars. Actual scenario represents the observed scale-up of HIV, TB, and malaria services over the study period. Constant coverage scenario represents a counterfactual with coverage of HIV, TB, and malaria services held constant at the year 2000 levels for each country over the study period.

	Number of countries included in analysis	Averted inpatient bed-days (%)		Cost savings (%)	
		Whole period (2000-23)	Final year (2023)	Whole period (2000-23)	Final year (2023)
Total	108	2.7 (0.6, 14.1)	4.4 (1.1, 21.6)	1.3 (0.1, 4.7)	1.6 (0.2, 5.9)
Disease					
HIV	108	0.7 (0.2, 3.0)	1.3 (0.4, 5.6)	0.2 (0.05, 0.8)	0.3 (0.07, 1.5)
TB	51	4.9 (1.8, 9.6)	7.2 (3.0, 16.1)	1.5 (0.7, 2.0)	2.5 (0.9, 4.0)
Malaria	55	3.2 (0.2, 6.9)	3.8 (0.1, 8.0)	1.3 (0.1, 3.2)	1.5 (0.07, 3.8)
World Bank region					
East Asia and Pacific	13	2.3 (0.4, 5.1)	3.0 (0.7, 7.6)	0.7 (0.3, 1.3)	0.7 (0.3, 1.2)
Europe and Central Asia	13	0.7 (0.2, 1.5)	2.3 (0.7, 4.0)	0.8 (0.2, 2.1)	1.3 (0.3, 3.6)
Latin America and Caribbean	18	0.9 (0.5, 1.1)	1.5 (0.9, 2.3)	0.1 (0.09, 0.2)	0.2 (0.08, 0.3)
Middle East and North Africa	9	0.1 (0.04, 0.14)	0.2 (0.1, 0.5)	0.03 (0.02, 0.05)	0.08 (0.05, 0.1)
South Asia	8	3.6 (0.1, 7.1)	4.9 (0.3, 11.5)	0.9 (0.04, 1.5)	1.0 (0.06, 2.3)
Sub-Saharan Africa	47	18.0 (7.8, 34.4)	31.8 (9.2, 54.7)	6.1 (2.2, 8.8)	9.5 (2.7, 19.7)
Income classification					
Low income	25	16.3 (8.9, 33.7)	22.9 (8.7, 53.1)	4.4 (1.8, 8.8)	5.1 (2.7, 14.0)
Lower middle income	44	4.5 (0.8, 14.4)	6.3 (1.2, 22.3)	1.3 (0.3, 4.2)	2.0 (0.4, 6.6)
Upper middle income	39	0.9 (0.3, 1.8)	1.7 (0.5, 3.5)	0.2 (0.09, 0.8)	0.3 (0.08, 1.2)

Table 2. Estimates of inpatient bed days averted as a percentage of national hospital bed capacity and costs savings as a percentage of domestic government health expenditure, for actual scenario compared to constant coverage scenario, 2000-23.

Point estimates represent median across modeled countries. Values in parentheses represent interquartile range (25th and 75th percentiles) of country-level values.

Figures

Figure 1. Averted primary health care utilization and associated cost savings due to scale-up of HIV, TB, and malaria interventions from 2000 to 2023, by year, country, and disease.

Results shown for 10 modeled countries with the highest HIV prevalence, TB incidence rate, and malaria incidence rate in 2023.[32-34]

Figure 2. Averted inpatient bed-days due to scale-up of HIV, TB, and malaria interventions, as a percentage of national hospital bed capacity, 2000-23.

Figure 3. Cost savings due to scale-up of HIV, TB, and malaria interventions compared to domestic government health expenditures by country in 2023.

Plotted values represent nominal U.S. dollars.